WPA
TNXP icon

Wealth Preservation Advisors’s Tonix Pharmaceuticals TNXP Stock Holding History

Wealth Preservation Advisors’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-55
Closed -$756 – 868
2026
Q1 		$756 Buy
+55
New +$847 ﹤0.01% 724

Other funds holding TNXP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
II
Ishara Investments Los Angeles, California $136M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wealth Preservation Advisors's TNXP Position: Q2 2026 in Review

Wealth Preservation Advisors sold out of Tonix Pharmaceuticals (TNXP) in Q2 2026, closing a stake of 55 shares — an estimated $756 sold.

Wealth Preservation Advisors first reported a position in TNXP in Q1 2026 and held it in 1 quarter. The position peaked at $756 in Q1 2026. 103 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.

  • Wealth Preservation Advisors reported no remaining Tonix Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Wealth Preservation Advisors sold 55 Tonix Pharmaceuticals shares in Q2 2026, an estimated $756.
  • Wealth Preservation Advisors first reported a position in Tonix Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Wealth Preservation Advisors's Tonix Pharmaceuticals position peaked at $756 in Q1 2026.
  • 103 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.

Based on Wealth Preservation Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.